Pub Date : 2021-11-17DOI: 10.2174/1876386302114010032
Y. Siahaan, Jessica Herlambang, Cynthia Putri, P. Tiffani
Superior cluneal nerve entrapment is a neuropathic condition caused by the inclusion of the superior cluneal nerve that contributes to one of the causes of lower back pain leading to high morbidity. Several therapeutic modalities are available for superior cluneal nerve entrapment, including medications, physiotherapy, perineural injection, and surgery. Perineural injection with 5% dextrose has become therapeutic alternative in many cases of neuropathy, but its long-term effectiveness is unknown. This study described four patients with superior cluneal nerve entrapment with severe pain intensity treated with ultrasonography guided perineural 5% dextrose injection, resulting in significant clinical improvement during the 6-month evaluation. Perineural injection can be considered as long-term therapy in patients with superior cluneal nerve entrapment who have failed other conventional therapies.
{"title":"Ultrasound-guided Perineural Dextrose Injection for Treatment of Superior Cluneal Nerve Entrapment: Serial Case Report","authors":"Y. Siahaan, Jessica Herlambang, Cynthia Putri, P. Tiffani","doi":"10.2174/1876386302114010032","DOIUrl":"https://doi.org/10.2174/1876386302114010032","url":null,"abstract":"\u0000 \u0000 Superior cluneal nerve entrapment is a neuropathic condition caused by the inclusion of the superior cluneal nerve that contributes to one of the causes of lower back pain leading to high morbidity. Several therapeutic modalities\u0000 are available for superior cluneal nerve entrapment, including medications, physiotherapy, perineural injection, and surgery. Perineural injection with 5% dextrose has become therapeutic alternative in many cases of neuropathy, but its long-term effectiveness is unknown.\u0000 \u0000 \u0000 \u0000 This study described four patients with superior cluneal nerve entrapment with severe pain intensity treated with ultrasonography guided perineural 5% dextrose injection, resulting in significant clinical improvement during the 6-month evaluation.\u0000 \u0000 \u0000 \u0000 Perineural injection can be considered as long-term therapy in patients with superior cluneal nerve entrapment who have failed other conventional therapies.\u0000","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46723985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-10DOI: 10.2174/1876386302114010014
A. S. Eraghi, Iman Azizpour, Mikaiel Hajializade
Celecoxib is widely used in post-operative cases because of its ability to reduce postoperative opioid drug use. Currently, the use of this drug is common in post-operative cases. In various studies, pregabalin was used for the management of pain after spinal surgery to reduce the need for opioids. Since the treatment of tibia fractures and surgery is painful and has a long-term recovery, this study aimed to compare the effect of two drugs (pregabalin and celecoxib) on pain severity at 24 h postoperatively in patients having tibia fracture surgery. This would mark significant progress in taking the proper drug. In this probability clinical experiment, the sample consisted of 50 patients scheduled for tibia fractures, who were selected from the table of random numbers. Then, the patients were assigned into two groups: celecoxib (Group C) and pregabalin (Group P). In the first group, celecoxib was administered to patients at 1 h pre-operatively at a dose of 200 mg and 1 h post-operatively at a dose of 200 mg. In the second treatment group, patients received pregabalin at 1 h pre-operatively at a dose of 200 mg and 1 h post-operatively at a dose of 200 mg orally. Then VAS (visual analog scale) scores were recorded at 6, 12, and 24 h after surgery. Finally, using SPSS software, qualitative variables were compared according to their percentage by the Chi-square test. For quantitative analysis of variables, the mean value of each group was calculated. The comparison of means was made by t-test. The VAS score was considerably lower at 24 hours after surgery in the pregabalin group than in the celecoxib-treated group. However, after 6 and 12 h of surgery, no statistically meaningful difference was observed. A less analgesic effect was observed in the group treated with celecoxib than pregabalin, which was statistically significant. Pregabalin improves postoperative pain, and it has more analgesic effects than celecoxib.
{"title":"Comparison of Effects of Two Drugs (Pregabalin & Celecoxib) on 24 hours Post-Operative Pain Intensity in Patients Undergoing Tibia Fracture Surgery","authors":"A. S. Eraghi, Iman Azizpour, Mikaiel Hajializade","doi":"10.2174/1876386302114010014","DOIUrl":"https://doi.org/10.2174/1876386302114010014","url":null,"abstract":"\u0000 \u0000 Celecoxib is widely used in post-operative cases because of its ability to reduce postoperative opioid drug use. Currently, the use of this drug is common in post-operative cases. In various studies, pregabalin was used for the management of pain after spinal surgery to reduce the need for opioids.\u0000 \u0000 \u0000 \u0000 Since the treatment of tibia fractures and surgery is painful and has a long-term recovery, this study aimed to compare the effect of two drugs (pregabalin and celecoxib) on pain severity at 24 h postoperatively in patients having tibia fracture surgery. This would mark significant progress in taking the proper drug.\u0000 \u0000 \u0000 \u0000 In this probability clinical experiment, the sample consisted of 50 patients scheduled for tibia fractures, who were selected from the table of random numbers. Then, the patients were assigned into two groups: celecoxib (Group C) and pregabalin (Group P). In the first group, celecoxib was administered to patients at 1 h pre-operatively at a dose of 200 mg and 1 h post-operatively at a dose of 200 mg. In the second treatment group, patients received pregabalin at 1 h pre-operatively at a dose of 200 mg and 1 h post-operatively at a dose of 200 mg orally. Then VAS (visual analog scale) scores were recorded at 6, 12, and 24 h after surgery. Finally, using SPSS software, qualitative variables were compared according to their percentage by the Chi-square test. For quantitative analysis of variables, the mean value of each group was calculated. The comparison of means was made by t-test.\u0000 \u0000 \u0000 \u0000 The VAS score was considerably lower at 24 hours after surgery in the pregabalin group than in the celecoxib-treated group. However, after 6 and 12 h of surgery, no statistically meaningful difference was observed. A less analgesic effect was observed in the group treated with celecoxib than pregabalin, which was statistically significant.\u0000 \u0000 \u0000 \u0000 Pregabalin improves postoperative pain, and it has more analgesic effects than celecoxib.\u0000","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44698653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-05DOI: 10.2174/1876386302114010009
Silvana Bara, Gentian Vyshka, E. Ranxha
Trigeminal neuralgia, otherwise known under the French denomination of tic douloureux, is a chronic painful condition of a particular severity. Its descriptions are numerous and date back to centuries before. Although the anatomy of the trigeminal nerve has been well known, the pathophysiology and hence the treatment of this disease has been largely fortuitous. Disparate pharmacological and surgical approaches have been tried, some of them heralding a much-required therapeutic success. The authors make a brief description of the first sources that have systematized the disease, along with all therapies documented in a written form, especially from indexed journals of the two last centuries. Very few remnants of the previous therapies, actually considered obsolete, have survived to the proof of time; one of them relies on the possible role of the autonomic nervous system and anticholinergic therapies, later replaced from modern conservative and interventional approaches. Anticonvulsants have been, since 1940, the mainstay of the therapy, however, progressions in neurosurgery and mini-invasive procedures have substantially improved the quality of life and the prognosis of an otherwise very painful and chronic condition.
{"title":"A Historical Note on the Treatment of Trigeminal Neuralgia","authors":"Silvana Bara, Gentian Vyshka, E. Ranxha","doi":"10.2174/1876386302114010009","DOIUrl":"https://doi.org/10.2174/1876386302114010009","url":null,"abstract":"Trigeminal neuralgia, otherwise known under the French denomination of tic douloureux, is a chronic painful condition of a particular severity. Its descriptions are numerous and date back to centuries before. Although the anatomy of the trigeminal nerve has been well known, the pathophysiology and hence the treatment of this disease has been largely fortuitous. Disparate pharmacological and surgical approaches have been tried, some of them heralding a much-required therapeutic success. The authors make a brief description of the first sources that have systematized the disease, along with all therapies documented in a written form, especially from indexed journals of the two last centuries. Very few remnants of the previous therapies, actually considered obsolete, have survived to the proof of time; one of them relies on the possible role of the autonomic nervous system and anticholinergic therapies, later replaced from modern conservative and interventional approaches. Anticonvulsants have been, since 1940, the mainstay of the therapy, however, progressions in neurosurgery and mini-invasive procedures have substantially improved the quality of life and the prognosis of an otherwise very painful and chronic condition.","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45125841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-13DOI: 10.2174/1876386302114010001
Elias Habtu, Mamo Nigatu, Y. Ayele, Mebratu Tila, W. R. Demissie
Department of Anesthesia, College of Health Science, School of Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia Department of Biostatistics and Epidemiology, Institute of Health, Faculty of Public Health, Jimma University, Jimma, Ethiopia School of Anesthesia, Institute of Health, Faculty of Medical Science, Jimma University, Jimma, Ethiopia Department of Biomedical Sciences, Institute of Health, Faculty of Medical Science, Jimma University, Jimma, Ethiopia
{"title":"Practice of Regional Anesthesia and Its Associated Factors among Anesthesia Professionals Working in Teaching Referral Hospitals of Ethiopia; A Multi-center Study","authors":"Elias Habtu, Mamo Nigatu, Y. Ayele, Mebratu Tila, W. R. Demissie","doi":"10.2174/1876386302114010001","DOIUrl":"https://doi.org/10.2174/1876386302114010001","url":null,"abstract":"Department of Anesthesia, College of Health Science, School of Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia Department of Biostatistics and Epidemiology, Institute of Health, Faculty of Public Health, Jimma University, Jimma, Ethiopia School of Anesthesia, Institute of Health, Faculty of Medical Science, Jimma University, Jimma, Ethiopia Department of Biomedical Sciences, Institute of Health, Faculty of Medical Science, Jimma University, Jimma, Ethiopia","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"14 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2021-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42775567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.2174/1876386302013010052
J. Teitelbaum, Gaetano Morello, Sarah Goudie
Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases. The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS). An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide. Four 500 mg tablets twice daily for five weeks. Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms. 43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better. In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories: 1. 69.4% increase in energy(p<.001) 2. 69.2% increase in overall well-being(<.001) 3. 53.8% improvement in sleep(<.001) 4. 60.5% improvement in mental clarity(<.001) 5. 37.9% decrease in pain(<.013) 6. 34.8% decrease in anxiety(<.001) 7. 54.6% improvement in digestive symptoms(<.001) 8. FIQR 59.2 to 39.3(<.001) In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets. Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS. Clinical Trial Registration Number: NCT04381793.
{"title":"Nutritional Intervention in Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) A Unique Porcine Serum Polypeptide Nutritional Supplement","authors":"J. Teitelbaum, Gaetano Morello, Sarah Goudie","doi":"10.2174/1876386302013010052","DOIUrl":"https://doi.org/10.2174/1876386302013010052","url":null,"abstract":"\u0000 \u0000 Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases.\u0000 \u0000 \u0000 \u0000 The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS).\u0000 \u0000 \u0000 \u0000 An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide.\u0000 \u0000 \u0000 \u0000 Four 500 mg tablets twice daily for five weeks.\u0000 \u0000\u0000 \u0000 \u0000 Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms.\u0000 \u0000 \u0000 \u0000 43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better.\u0000 In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories:\u0000 1. 69.4% increase in energy(p<.001)\u0000 2. 69.2% increase in overall well-being(<.001)\u0000 3. 53.8% improvement in sleep(<.001)\u0000 4. 60.5% improvement in mental clarity(<.001)\u0000 5. 37.9% decrease in pain(<.013)\u0000 6. 34.8% decrease in anxiety(<.001)\u0000 7. 54.6% improvement in digestive symptoms(<.001)\u0000 8. FIQR 59.2 to 39.3(<.001)\u0000 In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets.\u0000\u0000 \u0000 \u0000 \u0000 Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS.\u0000 \u0000 \u0000 \u0000 Clinical Trial Registration Number: NCT04381793.\u0000","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42495265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-20DOI: 10.2174/1876386302013010042
Hadis Barkhori, F. Arefi, Kiavash Hushmandi, S. Daneshi, J. Salehi, Hamideh Barkhori, H. Rafee, M. Raei, L. Karimi
School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran Department of Nursing, School of Nursing, Jiroft University of Medical Sciences, Jiroft, Iran Department of Food Hygiene and Quality Control, Division of Epidemiology & Zoonoses, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran Department of Public Health, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran Department of Anesthesiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran Imam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft, Iran Research Center of Prevention and Epidemiology of Non-Communicable Disease, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran Behavioral Sciences Research Center, Life Style Institute, Nursing Faculty, Baqiyatallah University of Medical Sciences, Tehran, Iran
{"title":"Effects of Dexamethasone on Post-dural Puncture Headache in Patients Undergoing Orthopedic Surgery","authors":"Hadis Barkhori, F. Arefi, Kiavash Hushmandi, S. Daneshi, J. Salehi, Hamideh Barkhori, H. Rafee, M. Raei, L. Karimi","doi":"10.2174/1876386302013010042","DOIUrl":"https://doi.org/10.2174/1876386302013010042","url":null,"abstract":"School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran Department of Nursing, School of Nursing, Jiroft University of Medical Sciences, Jiroft, Iran Department of Food Hygiene and Quality Control, Division of Epidemiology & Zoonoses, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran Department of Public Health, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran Department of Anesthesiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran Imam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft, Iran Research Center of Prevention and Epidemiology of Non-Communicable Disease, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran Behavioral Sciences Research Center, Life Style Institute, Nursing Faculty, Baqiyatallah University of Medical Sciences, Tehran, Iran","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"13 1","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48457321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-20DOI: 10.2174/1876386302013010047
N. Sargolzaei, O. Rajabi, Yasaman Aleyasin, K. Ebrahimi
This was a split-mouth double-blind, randomized clinical trial pilot study. We randomized 15 patients, ages 35 to 64 years, with American Society of Anesthesiologists I and II with severe chronic periodontitis who were referred to the dental clinic for surgery, to receive 4 topical anesthetics (5%, 7.5%, and 10%) lidocaine prilocaine emulsion and 10% lidocaine hydrochloride topical anesthetic agent before local infiltration. Primary outcomes were assessing drug safety and pain level that measured by assessment of visual analog scale (VAS) scores of pain during LA injection in the first premolar and second molar in each maxillary quadrant in 15 patients corresponding to the posterior superior alveolar nerve (PSA) and secondary outcome was the relationship between age and gender regarding pain perception, and a total of 60 regions were analyzed.
{"title":"Pilot Randomized Clinical Trial Study: Comparative Study of 10% Lidocaine Hydrochloride Solution with Lidocaine Prilocaine Emulsion Prior to Local Anesthetic Injection","authors":"N. Sargolzaei, O. Rajabi, Yasaman Aleyasin, K. Ebrahimi","doi":"10.2174/1876386302013010047","DOIUrl":"https://doi.org/10.2174/1876386302013010047","url":null,"abstract":"This was a split-mouth double-blind, randomized clinical trial pilot study. We randomized 15 patients, ages 35 to 64 years, with American Society of Anesthesiologists I and II with severe chronic periodontitis who were referred to the dental clinic for surgery, to receive 4 topical anesthetics (5%, 7.5%, and 10%) lidocaine prilocaine emulsion and 10% lidocaine hydrochloride topical anesthetic agent before local infiltration. Primary outcomes were assessing drug safety and pain level that measured by assessment of visual analog scale (VAS) scores of pain during LA injection in the first premolar and second molar in each maxillary quadrant in 15 patients corresponding to the posterior superior alveolar nerve (PSA) and secondary outcome was the relationship between age and gender regarding pain perception, and a total of 60 regions were analyzed.","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"13 1","pages":"47-51"},"PeriodicalIF":0.0,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45564860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-13DOI: 10.2174/1876386302013010035
A. Papa, E. Saracco, M. D. Dato, P. Buonavolontà, A. Salzano, D. Tammaro, Beniamino Casale
The results of this data collection demonstrate the feasibility of DRG stimulation, the correspondence between the clinical indications at the DRG implant and what is commonly found in the literature on this technique.(18,20) Patients defined as clinical responders to DRG stimulation and so implanted with definitive IPG showed a sustained and long term efficacy. Eight patients had previously been implanted with a traditional SCS without any clinically relevant efficacy; they were then explained for unsatisfactory results. Six of them (75%) were later implanted with DRG, with long-term effectiveness. Another advantage of this therapy is the absence of positional effects and lead migration. The adverse events proved to be independent of the anatomical level of insertion; moreover, this series of cases show a lower incidence of lead migration than reported in the literature. In summary, DRGs have been ignored for too long, probably due to the technical difficulty of reaching their deep, almost extra-spinal anatomical position.
{"title":"Dorsal Root Ganglion Stimulation for the Management of Chronic Neuropathic Pain: A Retrospective Case Series during Four Years follow-up in a Single Center","authors":"A. Papa, E. Saracco, M. D. Dato, P. Buonavolontà, A. Salzano, D. Tammaro, Beniamino Casale","doi":"10.2174/1876386302013010035","DOIUrl":"https://doi.org/10.2174/1876386302013010035","url":null,"abstract":"The results of this data collection demonstrate the feasibility of DRG stimulation, the correspondence between the clinical indications at the DRG implant and what is commonly found in the literature on this technique.(18,20) Patients defined as clinical responders to DRG stimulation and so implanted with definitive IPG showed a sustained and long term efficacy. Eight patients had previously been implanted with a traditional SCS without any clinically relevant efficacy; they were then explained for unsatisfactory results. Six of them (75%) were later implanted with DRG, with long-term effectiveness. Another advantage of this therapy is the absence of positional effects and lead migration. The adverse events proved to be independent of the anatomical level of insertion; moreover, this series of cases show a lower incidence of lead migration than reported in the literature. In summary, DRGs have been ignored for too long, probably due to the technical difficulty of reaching their deep, almost extra-spinal anatomical position.","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"13 1","pages":"35-41"},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49515944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-25DOI: 10.2174/1876386302013010022
A. Chopade, P. A. Patil, Suraj N. Mali
Firstly, we have collected various parts of P. fraternus plant including the dried stems, leaves, and roots. In order to produce chronic inflammations, we further allowed injection to the left gastrocnemius muscle belly of rats with a freshly prepared solution of 3% carrageenan in normal saline (100μL). Thermal/heat hyperalgesia, mechanical hyperalgesia and muscle circumferences were determined in the current experimental model. In order to estimate, chronic pain modulating potential of P. fraternus, we have also studied histopathological studies and measurement of prostaglandin E-2 (PGE2).
{"title":"Pharmacological Aspects of Phyllanthus fraternus Standardized Extract (Rich in Lignans and Tannins) as a Pain Modulator","authors":"A. Chopade, P. A. Patil, Suraj N. Mali","doi":"10.2174/1876386302013010022","DOIUrl":"https://doi.org/10.2174/1876386302013010022","url":null,"abstract":"Firstly, we have collected various parts of P. fraternus plant including the dried stems, leaves, and roots. In order to produce chronic inflammations, we further allowed injection to the left gastrocnemius muscle belly of rats with a freshly prepared solution of 3% carrageenan in normal saline (100μL). Thermal/heat hyperalgesia, mechanical hyperalgesia and muscle circumferences were determined in the current experimental model. In order to estimate, chronic pain modulating potential of P. fraternus, we have also studied histopathological studies and measurement of prostaglandin E-2 (PGE2).","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"13 1","pages":"22-34"},"PeriodicalIF":0.0,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42947909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-18DOI: 10.2174/1876386302013010007
A. S. Parchure, Y. Peng
Pain is extremely multifaceted in nature, with physical injury being just one of its causes. The most commonly prescribed therapeutic intervention for acute as well as chronic pain (postoperative or otherwise) is Opioids. Opioid analgesics act via the opioid receptors (G protein coupled), that are widely distributed in the central and peripheral nervous system as well as the gastrointestinal tract, producing pain relief. The opioid analgesics are divided into distinct categories depending on the receptor type and their potency. Three major types of receptors mediate analgesic effects, namely, mu (μ), delta (δ) and kappa (κ). These are also further subdivided into different subtypes depending on the duration and onset as rapid-onset, shortacting and long-acting. The neurobiology behind opioid analgesia involves the mesolimbic (midbrain) reward system. There is also increasing scientific evidence that plasma pharmacokinetics, along with the CNS distribution of opioids, is greatly influenced by the P-glycoprotein (P-gp) efflux transporter. The ABCB1 gene is responsible for coding P-gp hence it was postulated that variability in the ABCB1 gene could potentially play an important role in determining why there is interindividual variability towards opioids therapeutic interventions Hence the primary purpose of this review was to compile and understand the research regarding the mechanisms of opioid actions and the effect of genetic variability (ABCB1 gene), on the P-gp transporters regarding their expression/function while also examining the opioid use, abuse and dependence and possibly coming up with some strategies to use pharmacogenomics as a potential tool for solving these issues
{"title":"The Impact of Opioid Analgesics and the Pharmacogenomics of ABCB1 in Opioid Dependence and Pharmacotherapies: A Short Review","authors":"A. S. Parchure, Y. Peng","doi":"10.2174/1876386302013010007","DOIUrl":"https://doi.org/10.2174/1876386302013010007","url":null,"abstract":"Pain is extremely multifaceted in nature, with physical injury being just one of its causes. The most commonly prescribed therapeutic intervention for acute as well as chronic pain (postoperative or otherwise) is Opioids. Opioid analgesics act via the opioid receptors (G protein coupled), that are widely distributed in the central and peripheral nervous system as well as the gastrointestinal tract, producing pain relief. The opioid analgesics are divided into distinct categories depending on the receptor type and their potency. Three major types of receptors mediate analgesic effects, namely, mu (μ), delta (δ) and kappa (κ). These are also further subdivided into different subtypes depending on the duration and onset as rapid-onset, shortacting and long-acting. The neurobiology behind opioid analgesia involves the mesolimbic (midbrain) reward system. There is also increasing scientific evidence that plasma pharmacokinetics, along with the CNS distribution of opioids, is greatly influenced by the P-glycoprotein (P-gp) efflux transporter. The ABCB1 gene is responsible for coding P-gp hence it was postulated that variability in the ABCB1 gene could potentially play an important role in determining why there is interindividual variability towards opioids therapeutic interventions Hence the primary purpose of this review was to compile and understand the research regarding the mechanisms of opioid actions and the effect of genetic variability (ABCB1 gene), on the P-gp transporters regarding their expression/function while also examining the opioid use, abuse and dependence and possibly coming up with some strategies to use pharmacogenomics as a potential tool for solving these issues","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"13 1","pages":"7-21"},"PeriodicalIF":0.0,"publicationDate":"2020-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46528229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：